We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Boehringer Ingelheim Expands GeneGo Licenses to Global Agreement

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Boehringer Ingelheim Expands GeneGo Licenses to Global Agreement"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

GeneGo, Inc. has announced that Boehringer Ingelheim have expanded their licensing agreement with GeneGo which now covers global locations and multiple departments.

The agreement covers a suite of software tools and databases for functional data analysis MetaCore, which is used for biomarker discovery, target identification and validation.

MetaCore features a set of tools for parsing, visualization and analysis of metabolic data and generation of merged metabolic/signaling networks starting from compounds structures. Such capability is key for toxicity studies and medicinal chemistry.

"We have been working for Boehringer Ingelheim more than a year and we are very pleased with their decision to expand their licenses. This year, we have already seen a substantial increase in the number of MetaCore seats within Pharmaceutical accounts, which is partly due to maturing of functional analysis technology," said Julie Bryant, GeneGo's VP of Business Development.

"We also think that the end users, wet lab scientists, see biologically relevant results using MetaCore that they are not getting from other tools," Bryant added.